Report overview
North America dominated the global respiratory virus infection drugs market in 2020. The trend is anticipated to continue during the forecast period. Strategies adopted by key players, such as product approvals & launch and mergers & acquisitions, well-established healthcare infrastructure, and early adoption of advanced therapeutics boost the growth of the respiratory virus infection drugs treatment market in the region.
This report aims to provide a comprehensive presentation of the global market for Respiratory Virus Infection Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Virus Infection Drugs. This report contains market size and forecasts of Respiratory Virus Infection Drugs in global, including the following market information:
Global Respiratory Virus Infection Drugs Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
The global Respiratory Virus Infection Drugs market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Antibiotics Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Respiratory Virus Infection Drugs include GlaxoSmithKline plc, Merck and Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi, CHIESI Farmaceutici S.p.A. and Orion Corporation, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
We surveyed the Respiratory Virus Infection Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Respiratory Virus Infection Drugs Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Respiratory Virus Infection Drugs Market Segment Percentages, by Type, 2023 (%)
Antibiotics
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Cough Suppressants
Nasal Decongestants
Others
Global Respiratory Virus Infection Drugs Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Respiratory Virus Infection Drugs Market Segment Percentages, by Application, 2023 (%)
Hospital Pharmacies
Drug Stores
Retail Pharmacies
Clinics
Others
Global Respiratory Virus Infection Drugs Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Respiratory Virus Infection Drugs Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Respiratory Virus Infection Drugs revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Respiratory Virus Infection Drugs revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline plc
Merck and Co., Inc.
AstraZeneca
Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Sanofi
CHIESI Farmaceutici S.p.A.
Orion Corporation
Cipla, Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Respiratory Virus Infection Drugs, market overview.
Chapter 2: Global Respiratory Virus Infection Drugs market size in revenue.
Chapter 3: Detailed analysis of Respiratory Virus Infection Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Respiratory Virus Infection Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
